Which generation of targeted drug is Ceritinib? Its status and application in treatment

Ceritinib, also known as Ceritinib, is a second-generation ALK inhibitor targeted drug, mainly used to treat ALK-positive non-small cell lung cancer (NSCLC). Compared with the first-generation ALK inhibitor crizotinib, ceritinib has stronger ALK inhibitory activity, especially in the treatment of drug-resistant mutations or central nervous system (CNS) metastasis. Therefore, it is often used as a subsequent medication option after crizotinib treatment failure.

In clinical application, ceritinib has been shown to significantly prolong the progression-free survival (PFS) of ALKpositive NSCLC patients, while having a high objective response rate (ORR). Its ability to penetrate the blood-brain barrier also gives it a unique advantage in treating patients with brain metastases. Ceritinib is often the preferred option for patients with crizotinib resistance or central nervous system metastasis.

Although ceritinib plays an important role in treatment, its use also has certain limitations. For example, gastrointestinal side effects (such as nausea, diarrhea, vomiting, etc.) are relatively common, which may affect patient tolerance. In addition, with the advent of more third-generation ALK inhibitors (such as lorlatinib), the clinical position of ceritinib is being re-evaluated, but it still has strong application value in some patients, especially when resources are limited or intolerant to new drugs.

In general, ceritinib, as a second-generation ALK targeted drug, plays an important role in the treatment of ALK-positive non-small cell lung cancer, especially as a treatment option after resistance to crizotinib. With the development of precision medicine, clinicians will rationally select different generations of ALK inhibitors based on the patient's genetic mutation and disease progression stage to achieve individualized treatment goals.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib